New IT Media Disposal Program From Kroll Ontrack

Kroll Ontrack Goes Green with a New IT Media Disposal Program

Erasure and Recycling Services Help Businesses and Individuals Safeguard Critical Information and the Environment

MINNEAPOLIS--  May 13, 2008 --Kroll Ontrack®, the leading provider of data recovery and legal technologies products and services, today announced a new media disposal program to help businesses and individuals safely dispose of their end-of-lifecycle hard drives in an environmentally conscious way. This fast, secure and convenient erasure and disposal service allows organizations and individuals to protect one of their most important assets - their data.

Kroll Ontrack's media disposal program is comprised of two steps:

Data Erasing Solutions: Kroll Ontrack offers two solutions that completely remove all traces of information stored on storage media and a verification service that ensures no traces of information can be recovered from the media following an erasure procedure.

    * Ontrack Eraser software: An easy-to-use, highly flexible data erasure software tool, Ontrack® Eraser, uses overwriting procedures to permanently remove data and meet the most stringent standards for data removal.
    * Ontrack Eraser services: A convenient, end-of-lifecycle service performed by Kroll Ontrack specialists that offers complete removal of your data using a "degausser," a hardware device that destroys data using strong magnetic fields.

Media Disposal Services: Kroll Ontrack's environmentally friendly media disposal service ensures certain media is disposed of in a method that protects both the owner of the stored data and the environment. Technicians dismantle the devices removing good parts for re-use prior to disposal of the storage media. All other hard drive and storage device components are turned over to Kroll Ontrack's recycling vendor that separates materials such as metals, circuit boards, copper wiring and aluminum into different commodities that are recycled and re-used for other products. Any left over materials are discarded in a manner that ensures no materials are deposited in landfills or incinerators. Specifically, they are disassembled using an optimal mix of physical and mechanical demanufacturing techniques to separate out hazardous materials from recyclable components.

"With this service, customers now have a convenient means to make sure their media does not fall into the wrong hands and is disposed of in a method that will not harm the environment," said Jim Reinert, vice president of software and services, Kroll Ontrack. "This is especially critical as both businesses and home users are looking for a safe and easy way to get rid of their mounting end-of-lifecycle machines."

From more information regarding this service visit www.ontrackdatarecovery.com.

About Kroll Ontrack Inc.

Kroll Ontrack provides technology-driven services and software to help legal, corporate and government entities as well as consumers recover, search, analyze, produce and present data efficiently and cost-effectively. In addition to its award-winning suite of software, Kroll Ontrack provides data recovery, advanced search, paper and electronic discovery, computer forensics, ESI consulting, and trial consulting and presentation services. Kroll Ontrack is a technology services division of Kroll Inc., the global risk consulting company. For more information about Kroll Ontrack and its offerings please visit: www.krollontrack.com; www.ontrackdatarecovery.com; www.engeniumsearch.com; www.trialgraphix.com.
Contacts

Kroll Ontrack
Kaitlin Creager, 952-516-3581
kcreager@krollontrack.com

Oral Cancer Now Covered under Specialty Benefits Dental Plans

`Early Warning' for Oral Cancer Now Covered under UnitedHealthcare Specialty Benefits Dental Plans

Coverage Applies to New Screening Test Used by Dentists

GOLDEN VALLEY, Minn.-- May 13, 2008 --UnitedHealthcare Specialty Benefits now provides coverage under all of its insured dental plans for a new oral cancer screening test for potential abnormalities inside the mouth, including premalignant lesions and oral cancer.

The test, which uses light-contrast technology, can improve a dentist's ability to identify, evaluate and monitor lesions that are difficult to see using visual inspection under conventional lighting.

"Evidence shows that dentists can serve as a valuable 'early warning' system for patients who have signs of oral cancer," said Dr. Michael Weitzner, vice president of clinical product development for UnitedHealthcare Specialty Benefits dental unit.

More than 34,000 Americans will be diagnosed with oral or pharyngeal cancer this year. The death rate associated with this cancer is particularly high - not because it is hard to discover or diagnose, but due to the cancer being routinely discovered late in its development. Studies confirm that survival does correlate with stage, making early diagnosis and treatment optimal for this disease and may have a positive impact on an individual's medical costs (Journal of the American Dental Association, Vol. 132, Nov. 2001).

By covering this type of oral cancer screening, UnitedHealthcare Specialty Benefits dental unit is renewing its longstanding commitment to early detection of oral cancer. In addition to oral cancer screening, UnitedHealthcare Specialty Benefits dental plans have covered brush biopsies since 2005 when the American Dental Association first introduced a current dental terminology (CDT) code for the procedure. Screening is covered once a year for individuals, starting at age 30. UnitedHealthcare Specialty Benefits' focus on wellness continues to build programs and plan enhancements that promote individuals' ability to better manage their overall health as well as their future medical and dental costs.

About UnitedHealthcare Specialty Benefits

UnitedHealthcare Specialty Benefits offers a broad array of specialty benefits, including vision, dental, group and voluntary insurance, worksite individual insurance and non-insurance programs. UnitedHealthcare Specialty Benefits is a business unit of OptumHealth, the health and wellness unit of UnitedHealth Group, Inc. (NYSE:UNH). More information about OptumHealth can be found at www.optumhealth.com/.

Contacts

OptumHealth
Ann Fleischauer, Director, External Communications
763-797-2652

Tiny Computer Runs Linux, Development Tools, Controls, and Servers for $80

$80 Tiny Computer Runs Linux, Development Tools, Controls, and Servers

US embedded hardware OEM KwikByte is shipping a low-cost, tiny embedded system designed for general purpose computing, embedded controls, and database/web servers. KwikByte demonstrated the system running open-source packages such as Apache, MySQL, and PostgreSQL within a Debian environment.

Tempe, AZ  -  March 12, 2008 -- US embedded hardware OEM KwikByte demonstrated a complete, embedded Debian environment and applications running on a power-conscious, microcontroller-based system. The system is designed for general purpose computing, embedded controls, remote monitoring, and server applications.

The board used for the demonstration, KwikByte's KB9260, is based on the AT91SAM9260 microcontroller. The controller's small footprint reduces system size while the low power consumption allows the board to be powered by Power over Ethernet – PoE also known as IEEE 802.3af. By using PoE, a single Ethernet connection to the board can provide power as well as network connectivity. This minimizes facility installation costs.

The board supports minimal configurations like BusyBox and uClibc as well as larger installations like Debian. The Debian development kit was shown running a controls application built and debugged on the board (screen shot attached). No tools were required on a host PC as the system exports a virtual display over Ethernet. This configuration resides entirely within on-board Flash. The dev kit includes schematics and the board ships with recent Linux kernel, currently 2.6.24.

The number of general purpose I/O (GPIO) combined with programmable clocks, serial channels, analog input channels, and timer/counter/PWM channels make it ideal for embedded controls applications. Additionally, the USB host power supply was designed to provide extra power for most USB hard drives. Applications that require very large storage space are only limited by the size of an external hard disk and the entire system can be powered over the Ethernet cable.

System Details
- AT91SAM9260, ARM926EJ-S 200MHz
- 32/64 MB SDRAM
- 8 MB boot Flash
- 256 MB – 2 GB NAND Flash
- 10/100 Ethernet
- 1 x USB 2.0 host port
- 35 x GPIO, max
- 3 x serial channels including debug serial
- 4 x programmable clocks
- 3 x timer/counter/PWM channels
- 4 x analog input ADC channels
- Power options: Power over Ethernet, on-board voltage regulator, or external power supply
- Size: 3.1" x 3.1"

Availability
The KB9260 is shipping now with volume pricing of $79.99. A WinCE port is also available.

About KwikByte
KwikByte designs and manufactures embedded hardware systems. Founded in 2003, KwikByte is located in Tempe, AZ.

Press Contact: KwikByte
Company Name:
Phone: 480-303-7475
Website: www.kwikbyte.com

Practice-Changing Clinical Data Anticipated By Medtronic

Medtronic Anticipates 'Practice-Changing' Clinical Data for Interventional Cardiologists at EuroPCR

ENDEAVOR II Four-Year Results, Updated ENDEAVOR Pooled Safety Analysis, One-Year Results from E-Five Registry and TAPAS Trial - All Feature on Meeting's Scientific Program

MINNEAPOLIS-- May 12, 2008 --Medtronic, Inc. (NYSE:MDT), today announced plans for the release of new clinical data on the Endeavor® Zotarolimus-Eluting Coronary Stent System and the Export® Aspiration Catheter at EuroPCR in Barcelona this week, May 13-16.

"New data from the ENDEAVOR clinical program and the TAPAS trial have the potential to be practice-changing for interventional cardiology," said Prof. Anthony Gershlick of University Hospitals of Leicester in the UK. "As the evidence from this clinical research continues to build, it shows more and more definitively the advantages of the Endeavor drug-eluting stent for a broad range of patients with coronary artery disease and of thrombus aspiration with the Export Aspiration Catheter for a specific group of patients suffering myocardial infarction."

A summary of the data presentations related to Medtronic's product portfolio for interventional cardiology at EuroPCR follows:

    * On Tuesday, May 13, the late-breaking clinical trials session from 15:30 - 18:30 in Room 1 includes presentations by:

- Dr. Jean Fajadet (at approximately 15:45) of the four-year results from ENDEAVOR II, a prospective, randomized, multicenter, controlled trial that compared the Endeavor drug-eluting stent to the Driver bare-metal stent.
                                                        
- Prof. Bart de Smet (at approximately 16:30) of one-year results from TAPAS, a single-center trial designed to evaluate the effect of thrombus aspiration preceding percutaneous coronary intervention by using the Export Aspiration Catheter in patients with acute myocardial infarction.

    * On Thursday, May 15, the Medtronic-sponsored symposium titled "Patients and Stents: Learning and Progress," 5:00 - 6:30 pm in Room 1, features presentations by:

- Prof. Martin Rothman on the one-year results of 8,300 patients in E-Five, an international registry that investigated the performance of the Endeavor drug-eluting stent in routine clinical practice.
                                                        
- Prof. Ian Meredith on the updated ENDEAVOR pooled safety analysis, which includes 2,132 Endeavor patients (from ENDEAVOR I, II, II continued access, III and IV) - 678 of whom have now been followed for four years, 1,271 for three years, 1,290 for two and 2,093 patients for one year.

All times are local to Barcelona. Room numbers are for The Forum CCIB Convention Center, the venue for EuroPCR.

"The data we're presenting this week at EuroPCR illustrate the depth of innovation within the CardioVascular business at Medtronic and the growing breadth of our offering to interventional cardiologists," said Scott Ward, senior vice president of Medtronic and president of the CardioVascular business. "We are particularly excited to share the long-term results from the ENDEAVOR clinical program, which continue to illustrate significant performance advantages for patients and physicians, positioning Medtronic for market leadership in coronary stents."

In addition to attending these data presentations and other educational and scientific sessions, EuroPCR participants are encouraged to visit the Medtronic exhibit (booth #D04), which will feature highlights of the company's current and future cardiovascular innovations, including the:

    * Endeavor and Endeavor Resolute Zotarolimus-Eluting Coronary Stent Systems
    * Sprinter Legend Balloon Catheter
    * Export XT Aspiration Catheter
    * Defender Embolic Protection Filter
    * Complete SE (Self-Expanding) Peripheral Stent
    * Assurant Cobalt Balloon-Expandable Iliac Stent
    * Melody Transcatheter Pulmonic Heart Valve

Information on Medtronic's programs designed to foster "Innovation through Collaboration" in the fields of educational development (Academia) and clinical science (Scientia) will also be available at EuroPCR.

"As the trend of closer collaboration across medical specialties continues, our CardioVascular business is uniquely positioned to forge the partnerships necessary to find novel solutions to unmet patient needs," Ward added. "As the theme of our EuroPCR exhibit, 'Better Together,' suggests, we know from decades of experience the profound power of collaboration with the clinical community in the service of patients with chronic diseases."

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.

Contacts

Medtronic, Inc.
Joe McGrath, 707-591-7367 (Public Relations)
Jeff Warren, 763-505-2696 (Investor Relations)